Login to Your Account



Launches Arbitration Claim Against J&J

Basilea Shares Sink on Delay in EU Approval of Zevtera

By Cormac Sherida


Wednesday, February 25, 2009
Shares in Basilea Pharmaceutica AG dropped by more than 36 percent Tuesday on news that European Union (EU) approval of Zevtera (ceftobiprole), expected during the current quarter, would be delayed until at least the year end. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription